News

Number of news items returned: 1 to 20 records of 422

Launching in 2019: EMF Performance Centre Nerang

12 November 2018

(313 views)

  Launching in 2019: EMF Performance Centre Nerang   EMF co-founder Scott walks us through the Nerang facility to explain everything we can ...

BlueMount Capital Appointed as Corporate Advisor by Qponics Limited

09 November 2018

(329 views)

  BlueMount Capital Appointed as Corporate Advisor by Qponics Limited   BlueMount Capital is pleased to advise that we have been appointed Corporate ...

LAUNCH OF CUTTING EDGE SOLUTION TO COMBAT TOXIC SILICA DUST- Craig Penty from Guarda Group Holdings

07 November 2018

(271 views)

  LAUNCH OF CUTTING EDGE SOLUTION TO COMBAT TOXIC SILICA DUST - Craig Penty from Guarda Group Holdings   “The fight against death ...

"Fighting Silicosis With Product Innovation"

29 October 2018

(803 views)

  "Fighting Silicosis With Product Innovation"   "There are increasing reports of chronic illness, including silicosis and even deaths of trades people in ...

Congratulations, News and Events - Funding Strategies Connect October 2018

29 October 2018

(673 views)

Congratulations, News and Events - Funding Strategies Connect October 2018     Dear Reader, Welcome to the October 2018 edition of Funding Strategies Connect! We ...

EMF Opens Upper Coomera Location

24 October 2018

(943 views)

    EMF Opens Upper Coomera Location "We opened our latest edition to the EMF Group in September being EMF Performance Centre Upper ...

Walker Capital Closes Round 2

18 October 2018

(1192 views)

    Walker Capital Closes Round 2 "On behalf of Walker Capital, I am excited to announce the completion of Round 2 of ...

Conference report: SuperReturn Asia 2018, Hong Kong

16 October 2018

(813 views)

  Conference report: SuperReturn Asia 2018, Hong Kong     BlueMount Capital's Director, M&A, Flora Mok, attended the SuperReturn Asia Conference at the JW ...

An excellent night at the HKABA QLD Business Awards!

05 October 2018

(1341 views)

  An excellent night at the HKABA QLD Business Awards!   BlueMount Capital was honoured and delighted to be a finalist in the ...

Award Finalist and Introductions - Funding Strategies Connect September 2018

28 September 2018

(1404 views)

Award Finalist and Introductions - Funding Strategies Connect September 2018   Dear Reader, Welcome to the September 2018 edition of Funding Strategies Connect! I ...

Walker Capital Launches Affiliate Program

29 August 2018

(1726 views)

  "Become a CPA Affiliate and earn up to 5% per Referral   Partner with Walker Capital and Earn More? Walker Capital values relationships ...

"Engineered stone cutting with prototype Guarda saw for silica dust control"

28 August 2018

(2407 views)

    "This is our new prototype Guarda stone cutting saw. This saw was conceptualised and built in less than 3 weeks ...

Copper Introduction, News and Events - Funding Strategies Connect July August 2018

21 August 2018

(2725 views)

Copper Introduction, News and Events - Funding Strategies Connect July/August 2018   Dear Readers, Welcome to the July/August 2018 edition of Funding Strategies ...

"Guarda Systems to launch revolutionary new Concrete Saw at "World of Concrete" Trade Show in Jan 2019"

27 July 2018

(3095 views)

  "Guarda Systems to launch revolutionary new Concrete Saw at "World of Concrete" Trade Show in Jan 2019   Our new Edge Powercutter ...

"Walker Capital gears for UK, EU market entry ahead of potential three-five year exit - MD"

25 July 2018

(2290 views)

  "Walker Capital gears for UK, EU market entry ahead of potential three-five year exit - MD   Walker Capital, an Australian investment ...

Fin Tech Roll-up PictureWealth Reaches $25m FUM

18 July 2018

(3693 views)

  "PictureWealth passes important milestone   To our valued stakeholders, It has been a productive few months and we have passed an important milestone ...

'Killer Dust' - Guarda products offer solution

12 July 2018

(3844 views)

  'Killer Dust' - Guarda products offer solution   On Sunday, 8 July 2018, Network Ten's television panel program The Project aired a ...

Director Briefing with David Pettit from PictureWealth

03 July 2018

(3856 views)

  Please click on the link below to read the Director Briefing. For more information about PictureWealth, please click here.

Director Briefing with Michael Walker from Walker Capital

29 June 2018

(3935 views)

  Please click on the link below to read the Director Briefing. For more information about Walker Capital, please click here.

EOFY - A Time To Review Goals and Achievements - Funding Strategies Connect June 2018

29 June 2018

(3595 views)

  EOFY - A Time To Review Goals and Achievements - Funding Strategies Connect June 2018   Dear Readers, Welcome to the June 2018 ...

JNCI publication involving CytImmune's CYT-21625

10 March 18

 

"JNCI publication involving CytImmune's CYT-21625"

 

"Please find attached [via the link below] an article published in the most recent version of the Journal of the National Cancer Institute (JNCI). This publication reports on a series of animal experiments comparing CytImmune's second generation nanomedicine, CYT-21625, against the commonly used chemotherapy, paclitaxel.


Key points:

1) CYT-21625 was safe with no toxicities observed.
2) The study involved three cancer models:
• Two thyroid cancers, traditional mouse xenograft models
• One Pancreatic neuroendocrine cancer, a genetically engineered mouse model.
3) Both anaplastic thyroid cancer (ATC) and pancreatic neuroendorine cancer (PNETs) are rare/orphan diseases, and have abysmal 5 year survival rates -- less than 5% for ATC and 16% for PNET patients with advanced disease.
4) CYT-21625 out-performed paclitaxel as measured by overall survival and using biological indicators that were specific to each cancer and model used.
We believe this study confirms the potential of the the Aurimune platform to deliver existing cancer drugs more effectively and with fewer toxic side effects. The paper concludes:

"CYT-21625 is effective in mice with PNETs [Pancreatic NeuroEndocrine Tumors] and metastatic human thyroid cancer with no toxicities. Thus, CYT-21625 should be studied in patients with advanced PNETs and thyroid cancer."

*Note that this study also used a CYT-6091 monotherapy as a control. As expected in this setting, while CYT-6091 showed some limited efficacy, it was inferior to therapies in which TNF is delivered in combination with chemotherapy. "

 

David Oarr, Chief Communications Officer, Project Karkinos, 10 March 2018.

Additional Documents

JNCI_CYT21625